Summary Each year, the American Heart Association (AHA), in conjunction with the National
Institutes of Health and other government agencies, brings together in a single document the …

Metformin is an effective agent with a good safety profile that is widely used as a first-line
treatment for type 2 diabetes, yet its mechanisms of action and variability in terms of efficacy …

Diabetes is not a single homogeneous disease but composed of many diseases with
hyperglycaemia as a common feature. Four factors have, historically, been used to identify …

The current classification system presents challenges to the diagnosis and treatment of
patients with diabetes mellitus (DM), in part due to its conflicting and confounding definitions …

Background In the treatment of type 2 diabetes, GLP-1 receptor agonists lower blood
glucose concentrations, body weight, and have cardiovascular benefits. The efficacy and …

Genome-wide association studies have implicated around 250 genomic regions in
predisposition to type 2 diabetes, with evidence for causal variants and genes emerging for …

Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its
mechanism of action remains unclear. Here the Metformin Genetics (MetGen) Consortium …

Diabetes mellitus has become one of the most challenging public health problems today.
There are still various deficiencies that remain in existing therapeutic drugs. With increasing …

Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global
epidemic. In order to achieve optimal glucose control, it is often necessary to rely on …

Current pharmacological treatment of diabetes is largely algorithmic. Other than for
cardiovascular disease or renal disease, where sodium–glucose cotransporter 2 inhibitors …